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There has been interest in the literature in the possible existence of a gene that predisposes to both breast cancer (BC) and
colorectal cancer (CRC). We describe the detailed characterisation of one kindred, MON1080, with 10 cases of BC or CRC invasive
cancer among 26 first-, second- or third-degree relatives. Linkage analysis suggested that a mutation was present in BRCA2. DNA
sequencing from III: 22 (diagnosed with lobular BC) identified a BRCA2 exon 3 542G4T (L105X) mutation. Her sister (III: 25) had BC
and endometrial cancer and carries the same mutation. Following immunohistochemical and microsatellite instability studies, mutation
analysis by protein truncation test, cDNA sequencing and quantitative real-time PCR revealed a deletion of MSH2 exon 8 in III: 25,
confirming her as a double heterozygote for truncating mutations in both BRCA2 and MSH2. The exon 8 deletion was identified as a
14.9kb deletion occurring between two Alu sequences. The breakpoint lies within a sequence of 45bp that is identical in both Alu
sequences. In this large BC/CRC kindred, MON1080, disease-causing truncating mutations are present in both MSH2 and BRCA2.
There appeared to be no increased susceptibility to the development of colorectal tumours in BRCA2 mutation carriers or to the
development of breast tumours in MSH2 mutation carriers. Additionally, two double heterozygotes did not appear to have a
different phenotype than would be expected from the presence of a mutation in each gene alone.
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BRCA1 and BRCA2 are the most important susceptibility genes for
breast and ovarian cancer, and mutations in these two genes
account for 480% of all kindreds with hereditary breast/ovarian
cancer and for about 2–3% of breast cancer (BC) cases overall.
Hereditary nonpolyposis colorectal cancer (HNPCC) is the most
common form of hereditary colorectal cancer (CRC) (Lynch and
de la Chapelle, 1999) and is responsible for 0.5–3% of all cases of
CRC. Mutations in the DNA repair genes MLH1 and MSH2
segregate in up to 90% of HNPCC pedigrees (Peltomaki, 2001).
Several groups have studied the genetic relationship between
breast and colorectal cancer, with varying findings. In one large
Dutch family with a segregating BRCA1 mutation, there are several
mutation carriers who have developed CRC. However, detailed
analysis suggested that the BRCA1 mutation was not contributing
to the CRCs observed. By contrast, in a large international study,
Thompson et al (2002) observed a relative risk of 2.03 (Po0.001)
for CRC in BRCA1 mutation carriers, compared with general
population cancer incidence. Studies in HNPCC kindreds have
shown no excess of BC, or have shown that when BC does occur,
microsatellite instability (MSI), a hallmark of HNPCC-related
cancer, is usually absent (Aarnio et al, 1995; Caluseriu et al, 2001).
Interestingly, Borg et al reported a family with two missense
mutations in MLH1 and a single truncating mutation in BRCA1.
The double heterozygote for the missense MLH1 and truncating
BRCA1 mutations developed BC but not colorectal or endometrial
cancer. The authors proposed a possible protective effect of BRCAI
deficiency against carcinogenic event in the colon (Borg et al,
2000).
In general, studies of female BC in HNPCC families have found
little evidence for MSI (Muller et al, 2002), but Boyd and colleagues
did find a role for MMR genes in BC susceptibility by performing
molecular genetics studies in five patients with BC from HNPCC
families. Microsatellite instability was observed in three of the five
tumours. In one family member with a 4-bp frame-shift mutation
in MLH1, expression of only the mutant allele was observed in the
BC tissue (Risinger et al, 1996).
It is not uncommon to see pedigrees with several cases of BC
and CRC. Given this clinical observation, and the data presented
above, the question of whether a single gene that predisposes to
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sboth BC and CRC exists is pertinent. Here, we describe the
investigation of one of the most convincing BC/CRC pedigrees
reported. MON1080 is a 26-member kindred that includes five
cases of CRC and five cases of BC (Figure 1). The family meets
Amsterdam criteria I for the diagnosis of HNPCC (Vasen et al,
1999), and nine of the 10 cases of cancer were diagnosed under the
age of 45 years.
PATIENTS AND METHODS
Patients
A detailed family history was taken from a total of 26 related
individuals from kindred MON1080. There were 17 female and
nine male subjects. The details are shown in Figure 1, and all
cancers were histopathologically confirmed, unless otherwise
indicated.
Immunohistochemistry (IHC) analysis
Immunohistochemistry for MLH1 and MSH2 proteins was
performed as a screening test for DNA mismatch repair-deficient
tumours. Mouse monoclonal antibodies G168-728 (MLH1,B D
Pharmingen, San Diego, CA, USA) and FE11 (MSH2, Oncogene
Research Products, San Diego, CA, USA) were used (Marcus et al,
1999). Surrounding normal mucosa and lymphocytes served as
internal positive controls. MLH1 and MSH2 IHC was performed on
the villoglandular polyp and the endometrioid adenocarcinoma of
the uterus from patient III: 25; on the anal carcinoma and
keratoacanthoma of patient III: 10; and on the astrocytoma of
patient II: 11. Immunohistochemistry was also performed on the
available BC from patients III: 5, III: 18, III: 17, III: 22 and III: 25
for ER (clone 6F11, Ventana, Tucson, AZ, USA), PR (clone 16,
Zymed, San Francisco, CA, USA), CDH-1 (clone 4A2 C7, Zymed,
San Francisco, CA, USA), MIB-1 (clone MMI, Novocastra, New-
castel, UK), P53 (clone DO-7, Dako, Denmark) and HER2 (clone
Tab 250, Zymed, San Francisco, CA, USA) proteins.
Microsatellite instability analysis
Microsatellite instability analysis was performed on microdissected
tissues using five MSI markers: BAT25, BAT26, D2S123, D5S346
and D17S250. According to international criteria, MSI is defined as
high-degree instability (MSI-H) if there is instability at two out of
five loci (Boland et al, 1998). Microsatellite instability was
performed on DNA extracted from the villoglandular polyp and
the endometrial cancer of patient III: 25, on the anal carcinoma
and keratoacanthoma of patient III: 10 and on the astrocytoma of
patient II: 11. Following extraction of DNA from paraffin-
embedded tissue, PCRs were performed using primer pairs, one
of which was fluorescently labelled with Cy5.5. The products were
visualised by fragment size analysis on an OpenGene System
(Visible Genetics, Ontario, Canada). Anal carcinoma is not a
common tumour in HNPCC kindreds, but we tested the anal and
skin tumour of patient III: 10 because skin tumours are a feature of
the HNPCC variant, Muir–Torre syndrome (MTS) and keratoa-
canthoma with MSI-H and loss of expression of MMR genes
(MSH2 or MLH1) have been reported to occur in MTS (Honchel
et al, 1994; Kruse et al, 1996; Entius et al, 2000).
DNA and RNA extraction and RT–PCR
Peripheral blood lymphocytes were separated from 16ml of whole
blood using the Accuspint System-Histopaque
s-1077 from Sigma
Diagnostics (St Louis, MO, USA). Total RNA was extracted using
Trizol Reagent (Invitrogen Canada, Burlington, Ontario, Canada).
DNA was extracted with the PUREGENE
s Genomic DNA Isolation
Kit from Gentra Systems (Minneapolis, MN, USA). Oligo(dT)-
primed cDNAs were synthesised using the SuperScriptt Pream-
plification System for First Strand cDNA Synthesis kit (Invitro-
gen). The complete open reading frame of MSH2 was then
amplified as two overlapping segments from 2ml of the cDNA
reaction using primers previously described by Luce et al (1995).
Protein truncation test (PTT) and sequence analysis of
MSH2 cDNA
We used the TNT
s Quick-Coupled Transcription/Translation kit
from Promega (Madison, WI, USA) for PTT. The PCR-amplified
cDNA segments were transcribed and translated in vitro in a
reaction mixture containing
35S-labelled methionine, and the
resultant polypeptides were separated on a 12% polyacrylamide
SDS gel, dried and subjected to autoradiography. Sequencing was
carried out on PCR-amplified cDNA segments by cycle sequencing
using Thermo Sequenase enzyme. PCR products were separated by
electrophoresis on low-melt agarose gel. The fragments were
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Figure 1 Hereditary breast and CRC Family MON1080. The numbers immediately under the symbols are individual numbers. The abbreviation ‘ut’
indicates untested. Mutations in brackets are inferred. MSH2¼MSH2 exon 8 deletion present. L105X¼BRCA2*L105X mutation present.
ENDO¼endometrial cancer.
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sexcised from the gel and purified using the QIAquick Gel
Extraction kit (QIAGEN, Mississauga, Ontario, Canada). The
purified fragments were then sequenced using the Thermo
Sequenase Cy5.5 Dye Terminator Sequencing Kit from Pharmacia
(Uppsala, Sweden).
MSH2 mutation analysis by real-time PCR
The real-time PCR was carried out as a duplex PCR amplifying
exon 8 MSH2 and CFTR exon 24 as an internal control in a
reaction volume of 25ml using the Brilliant QPCR kit (Stratagene,
Integrated Sciences, East Kew Victoria, Australia). TaqMan
fluorescent probes were synthesised according to the Applied
Biosystems primer express software program, allowing standard
amplification thermal cycling conditions (denaturation 951C for
10min, and subsequent cycles of 951C for 15s and 601C for 1min
for 40 cycles). The PCR reaction mixture consisted of 200nM each
of MSH2 exon 8-specific forward 50-AGAAATTATTGTTGG-
CAGTTTTTGTG-30 and reverse 50-CATATCTAAAGTTGTTTC-
TATCATTTCCTG-30 primers and the CFTR forward 50-
GAAGAGAACAAAGTGCGGCAG-30 and reverse 50-TTGCCGGAA-
GAGGCTCCT-30 primers, 100nM FAM-labelled MSH2 exon
8-specific probe (6FAM-CTCCTCTTACTGATCTTCGTTCTGAC-
TTCTCCAAG) and 400nM Hex-labelled CFTR exon 24 probe
(HEX-ACGATTCCATCCAGAAACTGCTGAACGA), to a final
concentration of 5.0mM MgCl2 and 200ng DNA sample. Ampli-
fications were carried out in the iCycler detection system (Biorad,
Regents Park, NSW, Australia) and analyses were performed in
triplicate.
MSH2 genomic DNA sequencing
The region containing the deletion was first amplified from
genomic DNA by long-range PCR using the Expand LT and
Expand 20Kb
PLUS PCR Systems (Roche, Indianapolis, IN, USA)
and the following primers: MSH2 IVS7-5K-F Tm 68 (50-ACTTCT-
TACTCCTTACTTCCTACTT-30), MSH2 IVS8-10K-R Tm 68 (50-
AACAGGAGAGACCGCTAATAGATA-30), TAAA-Rpt (50-TGAG-
TATTGCTCTCTTGCTATCTTG-30), and H2 EX8 ALUYF (50-
AACTTTGCCACCCATTTCAG-30). The deletion region was also
amplified using Platinum Taq (Invitrogen), the PCR Core Kit
(Qiagen), and the following primers: H2 EX8 ALUYF (50-
AACTTTGCCACCCATTTCAG-30) and MSH2, IVS8 10318R (50-
TTTGCTTGCTGATGTTCTGG-30). The reaction mixture was pre-
pared according to the manufacturer’s protocol. The following
thermocycling conditions were used: denaturation 951C for 2min,
and 35 cycles of 951C for 10s, 601C for 30s and 681C for 20–
30min, depending on the expected size of the wild-type product.
The PCR products that contained the expected deletion were cut
from the agarose gel, purified by QIAquick PCR purification Kit
(Quiagen, Chatsworth, CA, USA) and sequenced using the same
primers and the Thermo Sequenase Cy 5.5 Terminator Cycle
Sequencing Kit (Pharmacia) according to the manufacturer’s
instructions.
BRCA2 mutation analysis
DNA from individual III: 22 was sent to Myriad Genetics
Laboratories for a complete sequencing analysis of BRCA1 and
BRCA2. Following this, we used direct sequencing for individuals
III: 22 and III: 25. Other family members were subsequently tested
by single-strand conformation analysis (SSCA) using primers
flanking the mutation: F-50-CCGCTGTACCAATCTCCTGT-30 and
R-50-GAGACTGATTTGCCCAGCAT-30. PCR products were ampli-
fied using the Taq Gold amplification system (Perkin-Elmer) in the
presence of [
35S]dATP at 951C (30s), 601C (30s), 721C (30s) for 35
cycles, then separated on a 0.5 MDE gel for 6h 30min (25W,
41C). The presence of an additional band was evidence for the
presence of the mutation.
Haplotype analysis
Haplotype analysis was performed on each individual using single-
nucleotide polymorphisms (SNPs) and microsatellites within or
near BRCA2 or MSH2. Two tetranucleotide repeat microsatellites
(TTTA: intron 2; TAAA: intron 7) within MSH2 on chromosome 2
(Desai et al, 2000) were visualised by fragment size analysis on an
OpenGene System (Visible Genetics, Ontario, Canada). Five
polymorphic markers within or near BRCA2 (D13S1694,
D13S1695, D13S1697, D13S260 and D13S1698) were used to
distinguish between the chromosomes segregating in the family
(Table 1). Primer sequences and PCR amplification conditions can
be found in the Genome Database (GDB, http://gdbwww.gdb.org/
gdb/). PCR products were separated on denaturing acrylamide gels
and visualised by autoradiography.
RESULTS
Immunohistochemistry analysis
Several pathology samples from patient III: 25 were evaluated by
IHC. A moderately well differentiated, endometrioid adenocarci-
noma of the uterus showed weak nuclear staining of the carcinoma
with both antibodies. The second sample was a small villotubular
adenoma that showed strong nuclear staining with the MLH1
antibody, whereas no staining with the MSH2 antibody was
observed in the adenoma. Thus, there was no evidence of
mismatch repair-deficiency from inactivation of MLH1 in either
of these two samples, but the findings suggested MSH2 inactivation
in the colonic adenoma. Immunohistochemistry for MLH1 and
MSH2 was also performed on the anal squamous cell carcinoma
and keratoacanthoma from patient III: 10. Both lesions displayed
nuclear staining with the two antibodies, showing no evidence of
MLH1 or MSH2 inactivation in these samples. The results for the
brain tumour from II: 11 suggested inactivation of MSH2
(Figure 2), as shown by the lack of staining in the astrocytoma,
whereas IHC staining with the MLH1 antibody was normal.
Immunohistochemistry analysis of the available BCs is shown in
Table 2. In particular, III: 25, discussed above, developed an
invasive BC, which was ER/PR positive. None of the four breast
tumours analysed overexpressed HER2. Loss of E-cadherin
expression was noted in two breast cancers, whereas in one case
it was overabundant.
MSI analysis
Of the five samples subjected to MSI analysis, one (III: 25; DNA
from a villotubular adenoma) showed high degree of instability at
three out of five loci (BAT25, BAT26, D5S346), and the
endometrioid adenocarcinoma of the uterus was MSI-L (only
BAT-25 was unstable). Interestingly, patient II: 11, from whom
brain tumour tissue was available, showed MSI for BAT-25 and
D2S123; the other loci were stable (Figure 2). The keratoacanthoma
and the anal carcinoma from patient III: 10 were microsatellite
stable (MSS).
MSH2 mutation analysis
A truncated protein in the MSH2 gene was identified by PTT in
one woman (III: 25) who had a colon polyp and endometrial
cancer. To precisely locate the underlying cause of the truncation,
we used cDNA to amplify a segment spanning exons 5–9.
Electrophoretic separation of the PCR products showed the
presence of an additional smaller fragment. Sequencing of
this fragment revealed a deletion of exon 8 from the cDNA
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in a stop codon 12 nucleotides downstream of exon 9 (at
nucleotide 1398). DNA sequencing of the exon 8 and the flanking
intronic regions did not reveal any alteration of the consensus
splice sites, indicating that the exon 8 deletion was most
likely caused by a large genomic deletion of the region
encompassing exon 8.
In the quantitative real-time PCR analysis, normalised values for
nondeleted patients and normal controls are equal to one; the
normalised values for positive controls and deleted patients are
equal to zero. Real-time PCR analysis confirmed the presence of a
germline intragenic deletion encompassing exon 8 and flanking
intronic sequences in the patients showing a truncation in MSH2
by PTT (Table 1). DNA from II: 20 was not available for testing,
Table 1 Mutation and haplotype results in family MON1080
Generation/name BRCA2 genotype MSH2 genotype
I II III IV L105X
Haplotype
PTT
Haplotype
D13S1694 D13S1695 D13S1697 D13S1698 D13S260 TAAA-Rpt TTTA-Rpt
I: 1 [Negative] [2,2] [3,3] [1,3] [2,2] [4,5] [Positive] [170,186] [292, 288]
I: 2 [Positive] [2,3] [3,4] [2,1] [3,3] [5,4] [Negative] [178,178] [288, 292]
II: 1 Positive 2,3 3,4 3,1 2,3 5,4 Negative 178,186 288,292
II: 3 x[ ?,178] [?,292]
II: 4 x x
III: 2 Negative Negative 178,178 292,296
II: 7 [Positive] [2,3] [3,4] [3,1] [2,3] [5,4] [Negative] [186,178] [292,292]
II: 8 x[ 2,2] [3,3] [1,1] [2,3] [3,4] [Negative] [178,178] [292,288]
III: 4 Positive 2,3 3,4 1,1 2,3 3,4 Negative 178,186 292,292
III: 5 Positive 2,3 3,4 1,1 3,3 4,4 Negative 178,178 288,292
III: 6 Negative 2,2 3,3 1,3 3,2 4,5 Negative 178,178 288,292
III: 7 Positive 2,3 3,4 1,1 3,3 4,4 Negative 178,178 292,292
II: 9
II: 10 Negative [Negative]
III: 8 Negative Negative 178,186 288, 296
III: 9 Negative Negative 178/178 292/292
II: 11 [Negative] [x,2] [x,3] [x,2] [x,3] [x,5] [Positive] [170,178] [288,292]
II: 12 Negative 2,2 3,3 1,2 2,2 4,4 Negative 182,190 292,284
III: 10 Negative 2,2 3,3 1,2 2,3 4,5 Positive 170,190 288,284
III: 11 Negative 2,2 3,3 1,2 2,3 4,5 Negative 178,182 292,292
II: 13 [2,2] [3,3] [1,2] [2,3] [4,5] [Positive] [170,178] [288,292]
II: 14 Negative 2,2 2,4 2,2 3,2 1,2 Negative 174,190 284, 296
III: 12 Negative 2,2 [2,3] 2,1 3,2 1,4 Negative 174,178 296,292
III: 13 Negative 2,2 3,4 2,2 3,2 5,2 [Negative] 174,178 296,292
III: 14 Negative 2,2 3,4 2,2 3,2 5,2 Negative 174,178 296,292
III: 15 Negative 2,2 3,4 1,2 2,2 4,2 Positive 170,190 288,284
II: 16 Positive 2,3 3,4 1,1 2,3 4,4 Negative 178,186 288,292
II: 15 x x[ 174,?] [288,?]
III: 16 Negative Negative 174,186 288,292
III: 17 [Positive] 3,4 3,3 1,4 x
III: 18 Positive x
II: 18 Negative 2,2 3,3 1,2 2,3 4,5 Positive 170,178 288,292
II: 17 x [Negative] [178,178] [292,288]
III: 19 Negative Positive 170,178 288,292
IV: 1 Negative Negative 178,178 292,292
IV: 2 Negative Negative 178,178 292,292
III: 20 Negative Negative 178,178 288,292
III: 21 Negative Negative 178,178 288,292
II: 20 [Positive] [2,3] [3,4] [1,1] [2,3] [4,4] [Positive] [170,178] [288,292]
II: 21 Negative 1,1 1,3 1,1 1,2 1,5 Negative 178,190 284,292
III: 22 Positive 1,3 1,4 1,1 1,3 1,4 Negative 178,190 292,292
III: 23 Negative [1,2] 1,3 1,1 1,2 1,4 Negative 178,178 284,292
III: 24 Negative 1,2 1,3 1,1 1,2 1,4 [Negative] 178,190 292,292
III: 25 Positive 1,3 1,4 1,1 1,3 1,4 Positive 170,178 288,284
Italic: married to MON1080 family member. Bold number: distinguish the phase of the hapotypes. [Brackets and grey text]: result inferred (not from direct testing. II:10 -PTT
not done, status determined by real-time PCR). Since all results regarding the parents are inferred, the BRCA2 mutation was assigned arbitrarily to one individual from generation
I. Linked haplotype: BRCA2:3 ,4 ,1 ,3 ,4MSH2: 170, 288.
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cDNA (II: 21) (as well as haplotype analysis, see below) were
sufficient to confirm that II: 20, who died of CRC at 36 years of age,
was an obligate carrier.
MSH2 genomic DNA sequencing
Long-range PCR on genomic DNA was used to confirm the
deletion and to locate the region containing the breakpoint.
Different sets of primers were used to exactly characterise the
deletion at the junction site. A 1.9kb fragment containing the
deletion breakpoint was then amplified from genomic DNA with
the following primers: H2 EX8 ALUYF and MSH2, IVS8 10318R.
The exon 8 deletion was identified as a 14.9kb deletion occurring
between two Alu sequences. The localisation of the breakpoint lies
within a sequence of 45bp that is identical in both Alu sequences
that had been sequenced (Figure 3).
BRCA2 mutation analysis
DNA sequencing performed by Myriad Genetic Laboratories on
patient III: 22, who had lobular breast cancer, uncovered a BRCA2
exon 3 542G4T mutation, predicted to result in a truncated
protein (L105X). Patient III: 25 was shown to carry the same
mutation by DNA sequencing. Subsequently, SSCA analysis was
used to test all available family members for the 542G4T
Figure 2 (A) Microsatellite instability at various loci in astrocytoma of patient II: 20. (1) D2S123; (2) BAT 25 and (3) BAT 26. (B) Immunohistochemical
staining for MSH2 and MLH1 in the astrocytoma of patient II: 20. Upper panel: lack of staining for the MSH2 antibody indicating MSH2 inactivation in the
tumour. Lower panel: normal staining of MLH1 in the astrocytoma ( 400). (C) Protein truncation test shows a truncated protein in patients II: 18 and III:
25. (Lanes 1 and 2) the double-headed arrow indicates the protein product from the normal allele. The single arrow indicates the truncated protein. (D)
PCR products of cDNA segment including exons 5–9. Lanes 1–7: the double headed arrrow indicates PCR product of normal allele. Lanes 5 and 6: single
arrow indicates PCR product of mutant allele. (E) The first sequence of cDNA shows the junction of exons 7 and 8. The second sequence shows the exon 8
deletion found in patients with HNPCC-related cancers in family MON1080.
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smutation. We confirmed that II: 20, the father of III: 22 and III: 25,
is an obligate carrier of the BRCA2 exon 3 542G4T mutation and
an obligate double heterozygote because his widow (II: 21), the
mother of III: 22 and III: 25, does not carry the BRCA2 mutation or
the MSH2 mutation. Nine individuals were found to carry the
L105X mutation: five of them are affected by BC and one was
diagnosed with an ovarian papillary serous adenocarcinoma. Three
mutation carriers are not affected, II: 1 (a 74 years-old male), III: 4
(a 53-year-old female) and III: 7 (a 42-year-old female) (Figure 1
and Table 1).
Haplotype analysis
Haplotype analysis using polymorphic markers spanning MSH2
and BRCA2 was performed on 26 individuals. The MSH2 linkage
results were based on two markers, while the haplotype associated
with the BRCA2 exon 3 542G4T mutation was assessed using five
markers (Table 1). For both MSH2 and BRCA2, we identified a
common haplotype shared by all mutation carriers, consistent with
the inferred common ancestry. The five MSH2 exon 8 deletion
carriers (III:10, III:15, II:18, III:19 and III:25, Table 1) shared an
allele of identical size for two different MSH2 markers: TTTA-
Repeat (intron 2) and TAAA-Repeat (intron 8) (alleles 170 and
288). All carriers of the cDNA deletion of the exon 8 are
heterozygous for these two markers. A further four individuals
were classified as obligate mutation carriers on the basis of
reconstructed haplotypes and/or their position in the pedigree. We
used somatic cell hybrids containing a maternally derived or a
paternally derived chromosome 2 obtained from GMP Genetics
(Waltham, MA, USA) from individual II: 18 to confirm the phase
of the haplotype.
By direct genotyping, eight individuals in the MON1080 family
(II: 2, III: 4, III: 5, III: 7, II: 16, III: 18, III: 22, III: 25) were found to
share a common allele for five different BRCA2 markers (3, 4, 1, 3,
Table 2 Female breast cancer: pathological analysis and immunohistochemistry (IHC) results of selected markers in family MON1080
IHC
Family ID BRCA2/MSH2
Age at
diagnosis Vital status
Breast cancer
histopathology ER PR CDH-1 MIB-1 p53 HER2/ErbB-2
III: 5 mut/wt 42 Alive LCIS with six foci of infiltrating
lobular carcinoma
+++ +++   ++ +  
III: 17 mut/wt 33 Deceased DCIS with infiltrating ductal carcinoma (2.5cm).
Extensive lobular cancerisation
ND ND ND ND ND  
III: 18 mut/wt 33 Deceased Two foci (1.6 and 1cm) of
infiltrating lobular carcinoma
+++ + +++ + ++  
III: 22 mut/wt 34 Deceased Multicentric infiltrating lobular carcinoma +++ +++    +/  
III: 25 mut/mut 32 Alive LCIS with infiltrating lobular carcinoma (1.5cm).
Separate foci of DCIS
+ + ND ND ND ND
Mut¼heterozygous mutation; Wt¼wild-type; LCIS¼lobular carcinoma in situ; DCIS¼ductal carcinoma in situ;E R¼oestrogen receptor; PR¼progesterone receptor; CDH-
1¼E-cadherin.
Intron 7
Intron 7
Intron 8
Intron 8
Intron 8
Intron 7
Exon 7 Exon 8 Exon 8
Alu Y Alu Y
Intron 7:15 kb Intron 8:17.4 kb
Deletion: 14.9 kb
Common Alu Y sequence: breakpoint of the MSH2 exon 8 deletion
Figure 3 Characterisation of the MSH2 exon 8 deletion: the intron 7 Alu Y shares 83% identity with the intron 8 Alu Y. There are 17 Alu family
sequences in intron 7 and 18 Alu family sequences in intron 8. The MON1080 deletion is the result of the possible recombination between identical 45bp
sequences found in both AluY sequences.
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heterozygosity for the exon 8 deletion. Patient III: 17 was only
tested for three markers, but the result is consistent with the
presence of a BRCA2 mutation and she was diagnosed with breast
cancer at age 33 years. She is not a carrier of the MSH2 mutation.
In contrast, her cousin, III: 25, is a double heterozygote, and her
father is an obligate double heterozygote (Table 1). Three other
individuals are obligate mutation carriers.
DISCUSSION
We initially investigated the MON1080 family because of concern
regarding BC risk, but examination of the pedigree showed that the
incidence of CRC was just as high as that of BC (Figure 1). This
family seemed an appropriate kindred in which to look for a novel
breast–CRC predisposition gene. Linkage and molecular genetic
analyses, however, revealed two independent mutations: a muta-
tion in one MMR gene (MSH2) and in one BC susceptibility gene
(BRCA2). There is no evidence that women in this pedigree were
susceptible to BC solely because they carried an MMR gene
mutation, or that CRC was associated with BRCA2 mutations, as
has been previously suggested (Risch et al, 2001). Two individuals
(II: 20 and his daughter III: 25) are double heterozygotes. The
BRCA2 exon 3 542G4T mutation was present in nine family
members, among whom five women were diagnosed with BC and
one was diagnosed with ovarian cancer. Three carriers are
unaffected; two women had preventive mastectomies, and the
third was a male, who recently died of a noncancer-related
condition. In addition, eight MSH2 mutation carriers were
identified in the MON1080 family. Mutation status was inferred
for three individuals: two died of CRC and one died of an
astrocytoma following a rectal cancer. Three additional individuals
are affected by invasive cancer, while two remain unaffected by an
HNPCC-related cancer. However, among the unaffected indivi-
duals, one has had two colon polyps removed that were not
available for IHC or MSI testing and the other had both an anal
squamous cell carcinoma and a keratoacanthoma that were MSS
and did not show loss of MSH2 by IHC. The family history did not
reveal additional cases of keratoacanthoma or other skin cancers.
In patients with sebaceous gland adenocarcinoma (SGC) and a
personal or family history of CRC, the diagnosis of MTS is clear.
However, lack of a positive family history of SGC, absence of MSI
and normal expression of MSH2 in tumours of patients indicate
that the skin tumour can be considered a sporadic SGC (Entius
et al, 2000). In this case, we suspect the keratoacanthoma is a
sporadic occurrence and therefore a diagnosis of MTS is not
sustained.
The histopathology of the breast tumours in the BRCA2 exon 3
542G4T mutation carriers is interesting (Table 2). Of the five
female mutation carriers affected with breast cancer, one had a
ductal carcinoma in situ, with foci of microinvasion, but the other
four affected women had lobular invasive BC. Two of these four
had areas of lobular carcinoma in situ as well. Our finding of four
cases of lobular breast cancer in this family is consistent with
results from our previous hospital-based series of breast cancers
from Montreal, where we identified four BRCA2 mutation carriers
among 127 women with first primary invasive BCs (Chappuis et al,
2001). Two of the four BRCA2 mutation carriers had lobular BC,
and lobular BCs were statistically significantly overrepresented in
BRCA2 mutation carriers compared with noncarriers. Invasive
lobular BC is seen in 4% of BRCA1-related breast cancer and 4% of
sporadic controls, whereas 11% of BRCA2-related breast cancer is
of this subtype (Chappuis et al, 2000). Taken together, these
findings suggest that lobular BC is more commonly a feature of
germline BRCA2 mutation carriers than it is of BRCA1 mutation
carriers, and its presence could be an indication to commence
molecular studies of BRCA1/2 with BRCA2 analysis.
MSI-H and absence of MSH2 protein were observed in an
astrocytoma removed from II: 11 (Figure 2). This patient is an
obligate carrier of the MSH2 exon 8 deletion since his son carries
this mutation. Leung et al previously reported the presence of a
germline MMR gene mutation and MSI in patients with sporadic
gliomas. They analysed four patients with microsatellite-unstable
gliomas. Three had loss of MSH2 protein by IHC and carried a
germline MSH2 mutation. The fourth individual had a germline
MLH1 mutation. Interestingly, only one of them reported a family
history of CRC (Leung et al, 1998). Vasen et al (1996) suggested
that the possible histological types of brain tumours that can occur
in HNPCC kindreds include astrocytomas, oligodendrogliomas
and rarely ependyomas. Other studies have reported germline
MMR gene mutation in four patients with Turcot syndrome; three
reported that a close relative had had CRC (Vasen et al, 1996;
Miyaki et al, 1997; Hamilton et al, 2002).
Carriers of the MSH2 exon 8 deletion in this family share an
identical disease haplotype (Table 1). The haplotype of the
grandparents of the mutation carriers was determined by inference
and confirmed the consistency of our haplotype analysis. The
frequency of the haplotype of this MSH2 mutation in the general
population is not yet known, and it will be interesting to establish
if other kindreds with exon 8 deletions have the same haplotype
flanking MSH2 as reported here. Quantitative real-time PCR
analysis confirmed that the germline intragenic deletion encom-
passes exon 8 and flanking intronic sequences. It is present in all
patients showing a truncated protein by PTT for whom DNA was
available for testing. Long-range PCR confirmed the exon 8
deletion, by revealing a 1.9kb fragment containing the deletion
breakpoint. The 14.9kb deletion is the likely result of recombina-
tion between identical 45bp sequences found in both AluY
sequences (Figure 3). Wang et al characterised several large
genomic deletions in MSH2 (exons 11–14; exons 12–15) and
MLH1 (exon 4; exons 7–10) in patients suspected of HNPCC. They
sequenced five deletion breakpoints where Alu-repetitive elements
may be involved, but Alu-mediated recombination was not clearly
demonstrated. Interestingly, they detected a deletion of exon 8 in
the MSH2 gene in a patient by semiquantitative multiplex PCR, but
because of the large intronic sequence they could not characterise
the deletion breakpoint by long-rang PCR (Wang et al, 2003). By
contrast, in the kindred reported here, following the observation of
heterozygosity for intragenic MSH2 markers TAAA-Rpt (Table 1)
indicating that the deletion breakpoint would be localised down-
stream from this repetitive element, we were able to definitely
characterise this mutation (Figure 3). It seems highly likely that
other exon 8 cDNA deletions reported in the literature are due to
inter-Alu recombination as this region contains a large number of
Alu-repetitive elements (17 Alu family sequences in intron 7; 19
Alu family sequences in intron 8), which could promote such
deletions. The frequency of such large genomic deletion is
probably underestimated; the PCR-based methods used in most
molecular genetics laboratories do not allow their detection. In
fact, Charbonnier et al (2002) estimated that large MMR gene
rearrangements account for about 10% of the HNPCC cases in
France. Wijnen et al (1998) reported similar findings in the Dutch
population; 6.5% of the HNPCC cases are due to intragenic
deletion in MLH1 or MSH2. Genomic rearrangements are an
important component of the MMR mutation spectrum, and Alu-
mediated recombination are likely responsible of a large amount of
these intragenic deletions (Nystrom-Lahti et al, 1995; Viel et al,
2002).
In this large BC/CRC kindred, we identified disease-associated
mutations in both BRCA2 and MSH2. This is the first report of
double heterozygotes with truncating mutations in predisposition
genes for BC and CRC. The presence of the BRCA2 mutation
explained the occurrence of breast and ovarian cancer in the
kindred, and presence of the MSH2 mutation accounted for CRC,
endometrial and brain cancer (astrocytoma). One individual with
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mutation. There were also two individuals with lung cancer, one of
whom (II:7) is known to carry the BRCA2 mutation on the basis of
the reconstructed haplotype and the presence of this mutation in
his children. By reconstruction, he does not carry the MSH2
mutation. We could not establish the mutation status of the other
male subject with lung cancer (II:9) at either locus (Figure 1 and
Table 1).
Our results support the notion that early-onset BC in HNPCC
may be due to mutations in other genes, such as BRCA2, and that
early-onset CRC in BRCA1/2 may be due to mutations in MMR
genes, such as MSH2. This report describes the phenotype of the
first two individuals in whom truncating mutations in both genes
have been identified. Clearly, it is not possible to draw firm
conclusions from only two cases, but the double heterozygotes in
this kindred do not appear to have an earlier age of onset than
carriers of a single mutation, and the cancers appear to have
independent genetic aetiologies. Moreover, based on the data
presented here and other recent results (Muller et al, 2002), we do
not consider that a single highly penetrant BC–CCR cancer
susceptibility gene is likely to exist. Rather, in agreement with the
most recent epidemiological reports, our findings argue that the
two conditions (CRC and BC) are independent of each other
(Newschaffer et al, 2001). Kindreds with the phenotype reported
here are not frequently identified, but this detailed report
demonstrates how a single family can contribute more generally
to the understanding of the development of cancer in unusual
situations such as double heterozygosity.
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